An interventional study of Nicotinamide Riboside (NR) and Nicotinamide Riboside (NR) in Health Adult Subjects, sponsored by ZHANG Jiaqi. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by ZHANG Jiaqi · Not applicable, Interventional, and Other
Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺/NADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside [NR]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.
ZHANG Jiaqi is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Nicotinamide Riboside (NR)
Dietary Supplement: Nicotinamide Riboside (NR)
600 mg NR
300 mg NR
Substrate utilization (CHO and fat oxidation rate)
Time frame: From enrollment to the end of treatment at 4 weeks
Oxygen consumption
Time frame: From enrollment to the end of treatment at 4 weeks
Heart rate
Time frame: From enrollment to the end of treatment at 4 weeks
Blood glucose concentration
Time frame: From enrollment to the end of treatment at 4 weeks
Blood lactate concentration
Time frame: From enrollment to the end of treatment at 4 weeks
Peak power output
Time frame: From enrollment to the end of treatment at 4 weeks
Mean power output
Time frame: From enrollment to the end of treatment at 4 weeks
Rating of perceived exertion
Time frame: From enrollment to the end of treatment at 4 weeks
Muscle pain scale
Muscle pain scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle pain.
Time frame: From enrollment to the end of treatment at 4 weeks
Muscle fatigue scale
Muscle fatigue scale is a 5-point likert scale ranging from "1- Not at all" to "5- Extreme", with higher value indicating muscle fatigue.
Time frame: From enrollment to the end of treatment at 4 weeks
Height
Time frame: From enrollment to the end of treatment at 4 weeks
Weight
Time frame: From enrollment to the end of treatment at 4 weeks
Power output at VT1
Time frame: From enrollment to the end of treatment at 4 weeks
Health history questionnaire
This questionnaire includes questions regarding participant's present/past history of diseases and his/her family history of diseases.
Time frame: From enrollment to the end of treatment at 4 weeks
International Physical Activity Questionnaire (IPAQ)
IPAQ is a validated questionnaire to measure the physical activity of participants during the past 7 days. The score will be transformed to metabolic equivalents of tasks per week (METs/week), with higher value indicating greater participation in physical activity.
Time frame: From enrollment to the end of treatment at 4 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ZHANG Jiaqi